Press Release: C2 Therapeutics : C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of Its C2 CryoBalloon Focal Ablation System

REDWOOD CITY, Calif.--(BUSINESS WIRE)--C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company's CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 - 24